• Geneuro SA, of Geneva, said its clinical program in schizophrenia was awarded more than $700,000 by the Stanley Medical Research Institute to support a clinical trial in schizophrenic patients with a monoclonal antibody targeting a protein, called Env, of endogenous retroviral origin.